DE60315939D1 - Pharmazeutische zusammensetzung enthaltend ein androgen - Google Patents

Pharmazeutische zusammensetzung enthaltend ein androgen

Info

Publication number
DE60315939D1
DE60315939D1 DE60315939T DE60315939T DE60315939D1 DE 60315939 D1 DE60315939 D1 DE 60315939D1 DE 60315939 T DE60315939 T DE 60315939T DE 60315939 T DE60315939 T DE 60315939T DE 60315939 D1 DE60315939 D1 DE 60315939D1
Authority
DE
Germany
Prior art keywords
androgen
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315939T
Other languages
English (en)
Other versions
DE60315939T2 (de
Inventor
Robert Gyurik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CPEX Pharmaceuticals Inc
Original Assignee
Bentley Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60315939(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bentley Pharmaceuticals Inc filed Critical Bentley Pharmaceuticals Inc
Publication of DE60315939D1 publication Critical patent/DE60315939D1/de
Application granted granted Critical
Publication of DE60315939T2 publication Critical patent/DE60315939T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE60315939T 2002-04-19 2003-04-21 Pharmazeutische zusammensetzung enthaltend ein androgen Expired - Lifetime DE60315939T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37410302P 2002-04-19 2002-04-19
US374103P 2002-04-19
PCT/US2003/012235 WO2003088974A1 (en) 2002-04-19 2003-04-21 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE60315939D1 true DE60315939D1 (de) 2007-10-11
DE60315939T2 DE60315939T2 (de) 2008-05-21

Family

ID=29251138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315939T Expired - Lifetime DE60315939T2 (de) 2002-04-19 2003-04-21 Pharmazeutische zusammensetzung enthaltend ein androgen

Country Status (30)

Country Link
US (21) US7320968B2 (de)
EP (2) EP1425019B1 (de)
JP (1) JP2005519985A (de)
KR (2) KR100977896B1 (de)
CN (2) CN1662243B (de)
AR (2) AR039644A1 (de)
AT (1) ATE371456T1 (de)
AU (1) AU2003228612B2 (de)
BR (1) BR0309390A (de)
CA (1) CA2470200C (de)
CY (1) CY1109005T1 (de)
DE (1) DE60315939T2 (de)
DK (1) DK1425019T3 (de)
EA (1) EA009839B1 (de)
EG (1) EG24882A (de)
ES (2) ES2399900T3 (de)
HK (3) HK1082682A1 (de)
IL (1) IL164547A (de)
IS (2) IS2667B (de)
LT (1) LT5235B (de)
LV (1) LV13303B (de)
MX (1) MXPA04010311A (de)
MY (1) MY139721A (de)
NO (1) NO335864B1 (de)
NZ (1) NZ535970A (de)
PL (1) PL213976B1 (de)
SA (1) SA03240158B1 (de)
TW (1) TWI362932B (de)
WO (1) WO2003088974A1 (de)
ZA (1) ZA200408422B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
NZ553446A (en) * 2004-09-09 2010-05-28 Besins Int Lab Testosterone gels comprising propylene glycol as penetration enhancer
EP1634583A1 (de) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterongele enthaltend Propylenglykol als Resorptionsverstärker
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
AU2006299833B2 (en) 2005-10-12 2012-04-12 Besins Healthcare Luxembourg Sarl Improved testosterone gel and method of use
CN102088956A (zh) * 2008-05-09 2011-06-08 托马有限公司 氯胍用于治疗皮肤/粘膜疾病
JP2011522830A (ja) * 2008-06-05 2011-08-04 シーペックス ファーマシューティカルズ、インク． インスリンの鼻腔投与製剤
US20110097363A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically Effective Preparations of Insulin
EP2640398A4 (de) 2010-11-18 2014-05-14 White Mountain Pharma Inc Verfahren zur behandlung chronischer bzw. nicht linderbarer schmerzen und/oder erhöhung der schmerzschwelle bei einem patienten und pharmazeutische zusammensetzung zur verwendung darin
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
AU2012257490A1 (en) * 2011-05-15 2013-12-19 Acerus Pharmaceuticals Srl Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
US10568905B2 (en) * 2012-02-14 2020-02-25 Metabolic Therapy Inc. Pharmaceutical composition and method for treating retinal neurodegeneration
EP2833944A4 (de) 2012-04-06 2016-05-25 Antares Pharma Inc Verabreichung von testosteron-zusammensetzungen durch nadelgestützte düseninjektion
CA2885142A1 (en) 2012-09-20 2014-03-27 Leonard Austin Hensel Lock ring spreader
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) * 2017-11-02 2019-05-09 Rick Coulon Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) * 2020-11-29 2022-11-04 山东大学 一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989815A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Novel N-bis-azacyclopentan-2-onyl alkanes
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
BE843140A (fr) * 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3991203A (en) * 1975-06-19 1976-11-09 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4424210A (en) * 1980-04-04 1984-01-03 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4444762A (en) * 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4423040A (en) * 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4415563A (en) * 1980-04-04 1983-11-15 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclononan-2-ones
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4992422A (en) * 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en) 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de) 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
KR20040004416A (ko) * 1997-01-30 2004-01-13 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
DE19709960A1 (de) * 1997-03-11 1998-09-24 Aesculap Ag & Co Kg Verfahren und Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
JP4139860B2 (ja) * 1997-11-10 2008-08-27 ストラカン インターナショナル リミティッド 浸透増強および刺激減少システム
US6980952B1 (en) * 1998-08-15 2005-12-27 Texas Instruments Incorporated Source normalization training for HMM modeling of speech
EP1031564A1 (de) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Hemmer der Nicotinamidmonononukleotide-Bildung und deren Verwendung zur Krebstherapie
FR2801507B1 (fr) * 1999-11-30 2003-06-27 Pf Medicament Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
SK12682001A3 (sk) * 1999-12-08 2002-07-02 Pharmacia Corporation, Corporate Patent Department Celecoxib v tuhej forme so zvýšenou biologickou dostupnosťou
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US7214381B2 (en) * 2000-08-03 2007-05-08 Antares Pharma Ipl Ag Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EP2283865A1 (de) 2000-08-30 2011-02-16 Unimed Pharmaceuticals, LLC Verfahren zur Erhöhung des Testosteron-Spiegels und verwandter Steroidverbindungen bei Frauen
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
MXPA03001859A (es) * 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados.
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
DE20121209U1 (de) * 2000-12-22 2002-06-20 August Wolff Gmbh & Co Arzneim Gelzusammensetzung zur Behandlung von Hypogonadismus
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US7169107B2 (en) * 2002-01-25 2007-01-30 Karen Jersey-Willuhn Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system
EP1511494B1 (de) 2002-03-15 2020-08-19 Unimed Pharmaceuticals, LLC Pharmazeutische androgen-zusammensetzung und verfahren zur behandlung von depressionen
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259784A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Also Published As

Publication number Publication date
LT5235B (lt) 2005-06-27
ES2399900T3 (es) 2013-04-04
AU2003228612B2 (en) 2006-05-04
KR100977896B1 (ko) 2010-08-24
US20050192260A1 (en) 2005-09-01
KR20050011753A (ko) 2005-01-29
US7608609B2 (en) 2009-10-27
US7608608B2 (en) 2009-10-27
IS8870A (is) 2010-01-06
US20090118251A1 (en) 2009-05-07
KR20090079266A (ko) 2009-07-21
US20090124590A1 (en) 2009-05-14
NO335864B1 (no) 2015-03-09
WO2003088974A1 (en) 2003-10-30
MXPA04010311A (es) 2005-02-03
US7320968B2 (en) 2008-01-22
US20080275012A1 (en) 2008-11-06
CN102357098B (zh) 2014-12-17
PL372083A1 (en) 2005-07-11
ES2292964T3 (es) 2008-03-16
US20090124589A1 (en) 2009-05-14
US20090131387A1 (en) 2009-05-21
LV13303B (en) 2006-08-20
DK1425019T3 (da) 2008-02-04
TWI362932B (en) 2012-05-01
US7608607B2 (en) 2009-10-27
EP1425019A4 (de) 2004-11-17
IL164547A (en) 2011-01-31
NZ535970A (en) 2006-12-22
US20090118252A1 (en) 2009-05-07
US8063029B2 (en) 2011-11-22
IS7535A (is) 2004-11-17
EP1741433B1 (de) 2012-11-07
US20210308145A1 (en) 2021-10-07
CN102357098A (zh) 2012-02-22
JP2005519985A (ja) 2005-07-07
IL164547A0 (en) 2005-12-18
EP1425019A1 (de) 2004-06-09
US20080108590A1 (en) 2008-05-08
US7608605B2 (en) 2009-10-27
US7935690B2 (en) 2011-05-03
BR0309390A (pt) 2005-02-09
IS2946B (is) 2016-05-15
US20080275013A1 (en) 2008-11-06
HK1167332A1 (en) 2012-11-30
US7608606B2 (en) 2009-10-27
AU2003228612A1 (en) 2003-11-03
CN1662243A (zh) 2005-08-31
NO20045019L (no) 2005-01-14
US7608610B2 (en) 2009-10-27
US20130281416A1 (en) 2013-10-24
US20090118250A1 (en) 2009-05-07
SA03240158B1 (ar) 2007-02-17
HK1082682A1 (en) 2006-06-16
US20080103120A1 (en) 2008-05-01
US20210308146A1 (en) 2021-10-07
AR039644A1 (es) 2005-03-02
CA2470200C (en) 2005-07-26
US20140343025A1 (en) 2014-11-20
US20090192132A1 (en) 2009-07-30
LT2004101A (en) 2005-04-25
DE60315939T2 (de) 2008-05-21
MY139721A (en) 2009-10-30
EP1425019B1 (de) 2007-08-29
EG24882A (en) 2010-12-01
CY1109005T1 (el) 2014-07-02
ZA200408422B (en) 2006-06-28
EA009839B1 (ru) 2008-04-28
IS2667B (is) 2010-08-15
US20100081640A1 (en) 2010-04-01
EP1741433A1 (de) 2007-01-10
CA2470200A1 (en) 2003-10-30
ATE371456T1 (de) 2007-09-15
CN1662243B (zh) 2011-10-26
US20090192131A1 (en) 2009-07-30
US8178518B2 (en) 2012-05-15
US20130059828A1 (en) 2013-03-07
TW200408397A (en) 2004-06-01
AR087484A2 (es) 2014-03-26
PL213976B1 (pl) 2013-05-31
HK1098386A1 (en) 2007-07-20
US20150283153A1 (en) 2015-10-08
EA200401410A1 (ru) 2005-04-28
KR100952786B1 (ko) 2010-04-14
US20160129016A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
DE60315939D1 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
DE602004017381D1 (de) Zweiteilige selbstklebende Dentalmassen
PT1501534E (pt) Formulacoes farmaceuticas
DK1660104T3 (da) Farmaceutisk formulering indeholdende lanthanforbindelser
ATE380544T1 (de) Umhüllte feste darreichungsform
IS8460A (is) Lyfjafræðileg samsetning sem inniheldur kvetíapín
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
AU2003291103A8 (en) Pharmaceutical composition
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DK1587478T3 (da) Farmaceutisk sammensætning
AU2003250372A8 (en) Pharmaceutical composition
DE60310914D1 (de) Pulverzusammensetzung
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE60217369D1 (de) Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
IS7581A (is) Lyfjasamsetning
NO20034952D0 (no) Farmasöytiske forbindelser
DE10393889D2 (de) Medikament-Dosimeter-Kombipackung
NO20044164L (no) Farmasoytiske sammensetninger
DE10107261B4 (de) Pharmazeutische Zusammensetzung
ITMI20030705A1 (it) Composizione farmaceutica contenente n-acetil-l-cisteina
DE602004030921D1 (de) Pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CPEX PHARMACEUTICALS, INC. (N. D. GES. D. STAA, US

R082 Change of representative

Ref document number: 1425019

Country of ref document: EP

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUSSER,